BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 25626299)

  • 1. [Cytogenetic abnormalities in high-risk multiple myeloma].
    Ishida T
    Nihon Rinsho; 2015 Jan; 73(1):28-32. PubMed ID: 25626299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations.
    Chng WJ; Santana-Dávila R; Van Wier SA; Ahmann GJ; Jalal SM; Bergsagel PL; Chesi M; Trendle MC; Jacobus S; Blood E; Oken MM; Henderson K; Kyle RA; Gertz MA; Lacy MQ; Dispenzieri A; Greipp PR; Fonseca R
    Leukemia; 2006 May; 20(5):807-13. PubMed ID: 16511510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Correlation of chromosomal aberrations with prognostic markers in multiple myeloma patients--a single institution study].
    Lee JW; Lee JK; Hong YJ; Hong SI; Chang YH
    Korean J Lab Med; 2008 Dec; 28(6):413-8. PubMed ID: 19127104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India.
    Kadam Amare PS; Jain H; Nikalje S; Sengar M; Menon H; Inamdar N; Subramanian PG; Gujral S; Shet T; Epari S; Nair R
    Indian J Med Res; 2016 Oct; 144(4):536-543. PubMed ID: 28256461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytogenetic and molecular aberrations of multiple myeloma patients: a single-center study in Singapore.
    Lim AS; Lim TH; See KH; Ng YJ; Tan YM; Choo NS; Lim SX; Yee Y; Lau LC; Tien SL; Sathish K; Tan DC
    Chin Med J (Engl); 2013; 126(10):1872-7. PubMed ID: 23673102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.
    Sawyer JR
    Cancer Genet; 2011 Jan; 204(1):3-12. PubMed ID: 21356186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes.
    Mohamed AN; Bentley G; Bonnett ML; Zonder J; Al-Katib A
    Am J Hematol; 2007 Dec; 82(12):1080-7. PubMed ID: 17654686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential analysis of chromosome aberrations in multiple myeloma during disease progression.
    Wu KL; Beverloo B; Velthuizen SJ; Sonneveld P
    Clin Lymphoma Myeloma; 2007 Jan; 7(4):280-5. PubMed ID: 17324335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic Aberrations in Multiple Myeloma.
    Manier S; Salem K; Glavey SV; Roccaro AM; Ghobrial IM
    Cancer Treat Res; 2016; 169():23-34. PubMed ID: 27696256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
    Neben K; Jauch A; Bertsch U; Heiss C; Hielscher T; Seckinger A; Mors T; Müller NZ; Hillengass J; Raab MS; Ho AD; Hose D; Goldschmidt H
    Haematologica; 2010 Jul; 95(7):1150-7. PubMed ID: 20220069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases.
    Smadja NV; Leroux D; Soulier J; Dumont S; Arnould C; Taviaux S; Taillemite JL; Bastard C
    Genes Chromosomes Cancer; 2003 Nov; 38(3):234-9. PubMed ID: 14506697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.
    Fonseca R; Bergsagel PL; Drach J; Shaughnessy J; Gutierrez N; Stewart AK; Morgan G; Van Ness B; Chesi M; Minvielle S; Neri A; Barlogie B; Kuehl WM; Liebisch P; Davies F; Chen-Kiang S; Durie BG; Carrasco R; Sezer O; Reiman T; Pilarski L; Avet-Loiseau H;
    Leukemia; 2009 Dec; 23(12):2210-21. PubMed ID: 19798094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization are complementary techniques to detect cytogenetic abnormalities in multiple myeloma.
    Alpar D; de Jong D; Holczer-Nagy Z; Kajtar B; Savola S; Jakso P; David M; Kosztolanyi S; Kereskai L; Pajor L; Szuhai K
    Genes Chromosomes Cancer; 2013 Sep; 52(9):785-93. PubMed ID: 23720363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissecting karyotypic patterns in non-hyperdiploid multiple myeloma: an overview on the karyotypic evolution.
    Jimenez-Zepeda VH; Braggio E; Fonseca R
    Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):552-8. PubMed ID: 23856591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma.
    Rajkumar SV; Gupta V; Fonseca R; Dispenzieri A; Gonsalves WI; Larson D; Ketterling RP; Lust JA; Kyle RA; Kumar SK
    Leukemia; 2013 Aug; 27(8):1738-44. PubMed ID: 23515097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytogenetics of multiple myeloma.
    Trcić RL; Skelin IK; Sustercić D; Planinc-Peraica A; Ajduković R; Haris V; Kusec R; Begović D
    Coll Antropol; 2010 Mar; 34(1):41-4. PubMed ID: 20432732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
    Neben K; Jauch A; Hielscher T; Hillengass J; Lehners N; Seckinger A; Granzow M; Raab MS; Ho AD; Goldschmidt H; Hose D
    J Clin Oncol; 2013 Dec; 31(34):4325-32. PubMed ID: 24145347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
    Wu KL; Beverloo B; Lokhorst HM; Segeren CM; van der Holt B; Steijaert MM; Westveer PH; Poddighe PJ; Verhoef GE; Sonneveld P; ;
    Br J Haematol; 2007 Feb; 136(4):615-23. PubMed ID: 17223915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant.
    Qazilbash MH; Saliba RM; Ahmed B; Parikh G; Mendoza F; Ashraf N; Hosing C; Flosser T; Weber DM; Wang M; Couriel DR; Popat U; Kebriaei P; Alousi AM; Anderlini P; Naeem RC; Champlin RE; Giralt SA
    Biol Blood Marrow Transplant; 2007 Sep; 13(9):1066-72. PubMed ID: 17697969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent Cytogenetic Abnormalities in Multiple Myeloma.
    Chan NC; Chan NP
    Methods Mol Biol; 2017; 1541():295-302. PubMed ID: 27910031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.